Placebo Effect in the Treatment of Depression and Anxiety.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing published meta-analyses and FDA trial data without systematic review methodology reported
PubMed 31249537 · doi:10.3389/fpsyt.2019.00407
What was done
This narrative review synthesized published and unpublished clinical trial datasets, prior meta-analyses, and data submitted to the US Food and Drug Administration (FDA) to evaluate the magnitude of the placebo response in depression and anxiety treatments, as well as outcomes from alternative modalities like psychotherapy and physical exercise.
What was found
No quantitative data, effect sizes, or confidence intervals are reported in the abstract. The author states that clinical trials and meta-analyses consistently show that most benefits of antidepressants reflect placebo effects, the drug-placebo difference is not clinically meaningful and may stem from unblinding, placebo response rates in FDA data have remained stable over time, alternative interventions match drug efficacy without active medication side effects, and relapse rates are lower with psychotherapy and placebo than with antidepressants.
Why it matters
It reinforces a prominent skeptical perspective on antidepressant efficacy by arguing that active pharmacology contributes minimally beyond non-specific placebo mechanisms.
Limits
The abstract provides no quantitative metrics, search protocols, screening criteria, or risk-of-bias assessments. Because it is a narrative synthesis rather than a formal systematic review, it is vulnerable to selective citation and interpretive bias.
Cited by
- supports Placebo responses in depression studies are more stable and longer-lasting than antidepressant responses upon discontinuation of treatment.